Business context and reporting period
Important entity mismatch: The supplied filing is Frequency Therapeutics, Inc. (Nasdaq: FREQ), not Korro Bio, Inc. It is a Form 10-Q for the quarter ended March 31, 2022; the financial statements are unaudited. Frequency is a clinical-stage regenerative medicine company focused primarily on hearing-loss candidate FX-322, with additional programs FX-345 and FREQ-162 for multiple sclerosis.
Financial and operating results
Amounts below are in millions of dollars unless noted.
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Revenue | $0 | $4.651 | Down $4.651 |
| Research and development expense | $13.781 | $15.106 | Down $1.325 |
| General and administrative expense | $9.477 | $9.744 | Down $0.267 |
| Total operating expenses | $23.258 | $24.850 | Down $1.592 |
| Net loss | $23.386 | $20.375 | Loss widened $3.011 |
| Net loss per share | $0.67 | $0.60 | Loss per share increased |
| Cash used in operating activities | $17.343 | $25.474 | Use decreased $8.131 |
No product sales or gross margin were reported. Q1 2021 revenue came from recognition of the Astellas upfront payment; the related Phase 2a services were completed in June 2021, so no corresponding revenue was recognized in Q1 2022. R&D expense declined mainly because MS-program spending decreased by $1.335 million, partly offset by higher FX-322 spending. The net loss nevertheless increased as the prior-year quarter included revenue.
At March 31, 2022, cash and cash equivalents were $49.830 million and marketable securities totaled $74.941 million, for combined cash and securities of approximately $124.8 million. Total assets were $164.939 million; total liabilities were $52.269 million; and stockholders’ equity was $112.670 million. Term-loan liabilities were $15.0 million, split between $3.333 million current and $11.667 million long-term. The loan bears 4.75% at quarter-end, has interest-only payments through November 2022, and matures May 1, 2024. Q1 investing cash outflow of $12.662 million primarily reflected purchases of marketable securities, partly offset by redemptions; total cash, cash equivalents and restricted cash decreased $29.805 million.
Material changes, outlook and risks
- Management stated that existing cash, cash equivalents and marketable securities were expected to fund operating and capital needs into 2024, while cautioning that this estimate relies on assumptions and additional financing may be needed.
- On April 8, 2022, after quarter-end, the company announced a workforce reduction of approximately 30%, with estimated future cash outlays of about $1.2 million, primarily severance. Management said the action was intended to preserve capital and prioritize FX-322, FX-345 and the MS program.
- The Phase 2b FX-322-208 study was underway, designed to enroll approximately 124 subjects with noise-induced or sudden sensorineural hearing loss. The filing gives no clear expected completion date or trial-result date. Management anticipated submitting an IND for FX-345 in the second half of 2022 and targeted initiation of MS clinical development in 2023.
- Clinical results remain uncertain: the Phase 2a FX-322-202 trial did not show hearing-measure improvements versus placebo; the company attributed the finding to potential bias and a single baseline measure. The filing also reports no significant treatment effect versus placebo in the FX-322 presbycusis study, despite favorable safety observations.
- The company has no approved products and has incurred recurring losses. Key risks include clinical and regulatory failure or delay, dependence on FX-322, financing needs, reliance on contract manufacturers and research organizations, COVID-19 disruption, intellectual-property risks, and competition.
- Two shareholder lawsuits were disclosed: a consolidated securities class action and a Delaware shareholder suit. The company said it could not estimate a possible loss and recorded no accrual for either matter as of March 31, 2022.
- In April 2022, the CFO resigned; the filing says no search for a replacement was planned at that time. Management reported disclosure controls were effective at the reasonable-assurance level as of March 31, 2022.
Most important facts to verify
- Confirm the intended issuer: this filing is for Frequency Therapeutics, not Korro Bio.
- Check subsequent FX-322-208 enrollment, completion and efficacy disclosures, including how results compare with the Phase 2a findings.
- Monitor cash burn, investment balances, financing activity and whether the stated runway into 2024 remains achievable after the workforce reduction.
- Review the status and potential financial consequences of both shareholder lawsuits and the approximately $1.2 million restructuring costs.
- Verify debt repayment terms and covenant status, and track the FX-345 IND and MS-program development timelines.